14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ITRM vs SPRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas SPRO carries 44.8/100 (HOLD) at $0.74 (N/M Forward P/E, 16.9% operating margin).
Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SPRO 44.8/100 HOLD), SPRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -1982.3% operating margin) and revenue trajectory (-95.6% vs. -100.0% YoY).
Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs SPRO. Trailing 12-month operating profitability (ITRM -1982.3% vs SPRO 16.9%) and valuation multiples (ITRM N/M vs SPRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $46.2M market capitalization and 16.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ITRM vs SPRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas SPRO carries 44.8/100 (HOLD) at $0.74 (N/M Forward P/E, 16.9% operating margin). Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SPRO 44.8/100 HOLD), SPRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -1982.3% operating margin) and revenue trajectory (-95.6% vs. -100.0% YoY). Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SPRO leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with SPRO at -95.6% YoY revenue growth and +75.3% YoY earnings growth on $42M TTM revenue (7.4% gross margin, 16.9% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $42M for SPRO. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SPRO.
ITRM screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas SPRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-97.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus SPRO (-216.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, SPRO carries 176.6% implied volatility (46th %ile, Balanced (25th–60th %ile)), a 5.37x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.84β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.